Free Pharma Reference
Understanding Clinical Trial Phases
The drug development journey from lab to market — Phase I through IV durations, patient numbers, endpoints, FDA milestones, and success rates for clinical ops, regulatory, and BD teams.
Quick Answer
Clinical trials progress through Phase 0 (exploratory microdosing), Phase I (first-in-human safety and dosing), Phase II (proof-of-concept and dose optimization), Phase III (pivotal confirmatory trials), and Phase IV (post-marketing surveillance). Average IND-to-approval time is 8–12 years with ~10–12% overall success. Phase attrition is highest at Phase II (~31% success). This free reference covers durations, patient numbers, FDA milestones, and success rates by therapeutic area.
Phase Overview
| Phase | Also Called | Primary Goal | Typical Patients | Avg Duration | Success Rate |
|---|---|---|---|---|---|
| Phase 0 | Exploratory / Microdosing | PK/PD proof of concept | 10–15 | 1–3 months | N/A |
| Phase I | First-in-Human (FIH) | Safety, tolerability, dosing (MTD, DLT) | 20–100 | 1–2 years | ~63% |
| Phase II | Proof-of-Concept | Efficacy signal, dose optimization | 100–500 | 2–3 years | ~31% |
| Phase III | Pivotal | Confirmatory efficacy & safety vs. comparator | 300–3,000+ | 3–5 years | ~58% |
| Phase IV | Post-Marketing | Long-term safety, real-world effectiveness | 1,000–10,000+ | Ongoing | N/A |
Phase Summary Cards
Phase I — First-in-Human Studies
Primary objectives: Establish safety profile, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Study design: SAD (Single Ascending Dose) and MAD (Multiple Ascending Dose) studies are the standard Phase I design. Dose escalation proceeds based on pre-specified rules (e.g., modified 3+3, BOIN). In oncology, patients rather than healthy volunteers are typically enrolled.
Endpoints: Dose-Limiting Toxicities (DLTs), MTD, safety and tolerability, PK parameters (Cmax, AUC, t½), PD biomarkers.
Key regulatory submissions: IND required (US), Clinical Trial Authorisation (CTA) required (EU/MHRA). Approximately 20 healthy volunteers or cancer patients depending on indication.
What success looks like: Clean safety profile allowing dose escalation, identification of RP2D, PK/PD relationship established, go-decision for Phase II.
Phase II — Proof-of-Concept
Primary objectives: Generate initial evidence of efficacy, optimize dosing regimen, and define the target patient population for Phase III.
Study design: Phase IIa focuses on proof of concept with a small cohort to establish an efficacy signal. Phase IIb involves dose optimization with a larger, more defined population. Randomized Controlled Trials (RCTs) begin here.
Endpoints: Primary endpoint is typically an efficacy signal using a validated biomarker or surrogate endpoint (e.g., ORR in oncology, HbA1c in diabetes). Secondary endpoints include safety, PK, and patient-reported outcomes.
Key regulatory submissions: End-of-Phase 2 (EOP2) meeting with FDA to align on Phase III design, statistical approach, and endpoint selection before committing to pivotal trials. IND amendment required for new protocols.
What success looks like: Statistically or clinically meaningful efficacy signal in the target population, acceptable safety profile, clear dose selection, and regulatory agreement on Phase III design.
Phase III — Pivotal Trials
Primary objectives: Confirm efficacy and safety in a large, well-defined patient population to support regulatory approval. Pivotal trials are the gold standard evidence basis for NDA/BLA/MAA submission.
Study design: Gold standard: randomized, double-blind, placebo- or active-controlled. Globally conducted across multiple sites. Adaptive trial designs — with pre-specified rules to modify dose, sample size, or population based on interim data — are increasingly common and accepted by regulators.
Endpoints: Pre-specified primary endpoint (e.g., overall survival, progression-free survival, symptom score) and secondary endpoints defined in the statistical analysis plan (SAP).
Key regulatory submissions: Results form the basis for NDA (21 CFR 314) or BLA (PHS Act 351) in the US, and MAA in the EU. Pre-NDA meeting held before submission.
Cost & scale: Typical Phase III costs $100M–$500M+ and lasts 3–5 years. Studies often enroll 300 to 3,000+ patients across dozens of countries.
What success looks like: Statistical significance on the primary endpoint with a clinically meaningful effect size, acceptable safety, and a benefit-risk profile that supports regulatory approval.
Phase IV — Post-Marketing Studies
Primary objectives: Monitor long-term safety, generate real-world evidence (RWE), support label expansions, and fulfill post-marketing commitments (PMCs) required by regulators at approval.
Key activities:
Post-Marketing Surveillance (PMS): Ongoing safety monitoring via pharmacovigilance systems including spontaneous reporting, signal detection in MedDRA-coded databases, and periodic safety update reports (PSURs/PBRERs).
REMS studies: Risk Evaluation and Mitigation Strategy studies required by FDA when a drug's risks require special management beyond standard labeling.
Label expansions: New indications, pediatric dosing, new formulations, or new patient populations may be supported by Phase IV / sNDA data.
Paediatric studies: Required under PREA (Pediatric Research Equity Act) in the US and the Paediatric Regulation (PDCO) in the EU. Paediatric Investigation Plans (PIPs) are agreed before Phase III.
Real-world evidence (RWE): Registry studies, claims database analyses, and EHR studies generating evidence on effectiveness in broader populations beyond clinical trial settings.
Drug Development Timeline Overview
From initial discovery to market approval, drug development typically takes 10–15 years and costs $1–2 billion including the cost of failures.
Typical total timeline: 10–15 years from discovery to approval. Average total cost: $1–2 billion (including failures).
Key FDA Milestones & Review Clock
| Milestone | Timing |
|---|---|
| IND filing | Before Phase I — 30-day clinical hold review |
| End-of-Phase 1 meeting | After Phase I — optional, discuss Phase II design |
| End-of-Phase 2 meeting | After Phase II — align on Phase III design, endpoints, statistics |
| Pre-NDA meeting | Before NDA/BLA submission — format, content, labeling |
| NDA/BLA submission | After Phase III completion |
| Filing review | 60 days — completeness assessment (refuse-to-file possible) |
| PDUFA review clock (Standard) | 12 months from acceptance date |
| PDUFA review clock (Priority) | 6 months from acceptance date |
| Approval | 10–15 years from discovery (typical) |
Success Rates by Therapeutic Area (IND to Approval)
| Therapeutic Area | Approx. Success Rate (IND to Approval) |
|---|---|
| Oncology | 5–10% |
| Infectious Disease | ~20% |
| Cardiovascular | ~10% |
| CNS (Neurology / Psychiatry) | ~8% |
| Overall (all areas) | ~12% |
Pharma & Clinical Development Context
Phase-gate decisions drive portfolio capital allocation. Phase II attrition (~31% success) is the highest-value inflection point — EOP2 alignment with FDA on endpoints and sample size prevents costly Phase III failures. Adaptive designs, estimands (ICH E9 R1), and multi-regional trial planning (ICH E17) are increasingly standard in pivotal programs.
Cross-link to FDA Submission Types for IND/NDA/BLA pathways, Sample Size Calculator for power planning, ICH Guidelines for GCP (E6) and statistical principles (E9), and Pipeline Intelligence for phase distribution across indexed programs.
Evidence & Sources
- ClinicalTrials.gov Glossary — phase definitions
- FDA: Drug Development Process — step-by-step overview
- FDA: IND application procedures — 30-day review
- FDA Guidance: Adaptive Design Clinical Trials
- ICH Efficacy Guidelines — E6 GCP, E8, E9
Competitive landscape: NIH ClinicalTrials.gov (Glossary) provides official phase definitions but no success-rate data, FDA milestone tables, or therapeutic-area breakdowns. FDA's patient-facing drug development overview is simplified without Phase IIa/IIb distinction or EOP2 meeting guidance. NovaPharmaNews combines phase cards, success-rate tables, FDA milestone clocks, and regulatory cluster links in one searchable reference — free, no login.